498 related articles for article (PubMed ID: 7518514)
1. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
Arneric SP; Sullivan JP; Briggs CA; Donnelly-Roberts D; Anderson DJ; Raszkiewicz JL; Hughes ML; Cadman ED; Adams P; Garvey DS
J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
[TBL] [Abstract][Full Text] [Related]
2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
[TBL] [Abstract][Full Text] [Related]
3. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
Anderson DJ; Williams M; Pauly JR; Raszkiewicz JL; Campbell JE; Rotert G; Surber B; Thomas SB; Wasicak J; Arneric SP
J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
[TBL] [Abstract][Full Text] [Related]
4. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
Sullivan JP; Donnelly-Roberts D; Briggs CA; Anderson DJ; Gopalakrishnan M; Xue IC; Piattoni-Kaplan M; Molinari E; Campbell JE; McKenna DG; Gunn DE; Lin NH; Ryther KB; He Y; Holladay MW; Wonnacott S; Williams M; Arneric SP
J Pharmacol Exp Ther; 1997 Oct; 283(1):235-46. PubMed ID: 9336329
[TBL] [Abstract][Full Text] [Related]
5. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.
Gopalakrishnan M; Molinari EJ; Sullivan JP
Mol Pharmacol; 1997 Sep; 52(3):524-34. PubMed ID: 9281615
[TBL] [Abstract][Full Text] [Related]
6. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
Gopalakrishnan M; Monteggia LM; Anderson DJ; Molinari EJ; Piattoni-Kaplan M; Donnelly-Roberts D; Arneric SP; Sullivan JP
J Pharmacol Exp Ther; 1996 Jan; 276(1):289-97. PubMed ID: 8558445
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.
Sacaan AI; Reid RT; Santori EM; Adams P; Correa LD; Mahaffy LS; Bleicher L; Cosford ND; Stauderman KA; McDonald IA; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):373-83. PubMed ID: 8996218
[TBL] [Abstract][Full Text] [Related]
8. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
Lin NH; Gunn DE; Ryther KB; Garvey DS; Donnelly-Roberts DL; Decker MW; Brioni JD; Buckley MJ; Rodrigues AD; Marsh KG; Anderson DJ; Buccafusco JJ; Prendergast MA; Sullivan JP; Williams M; Arneric SP; Holladay MW
J Med Chem; 1997 Jan; 40(3):385-90. PubMed ID: 9022806
[TBL] [Abstract][Full Text] [Related]
10. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
Brioni JD; O'Neill AB; Kim DJ; Buckley MJ; Decker MW; Arneric SP
J Pharmacol Exp Ther; 1994 Oct; 271(1):353-61. PubMed ID: 7965735
[TBL] [Abstract][Full Text] [Related]
11. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.
Sullivan JP; Decker MW; Brioni JD; Donnelly-Roberts D; Anderson DJ; Bannon AW; Kang CH; Adams P; Piattoni-Kaplan M; Buckley MJ
J Pharmacol Exp Ther; 1994 Nov; 271(2):624-31. PubMed ID: 7965777
[TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
[TBL] [Abstract][Full Text] [Related]
13. Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine.
Khan IM; Yaksh TL; Taylor P
J Pharmacol Exp Ther; 1994 Jul; 270(1):159-66. PubMed ID: 8035312
[TBL] [Abstract][Full Text] [Related]
14. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
Arneric SP; Sullivan JP; Decker MW; Brioni JD; Bannon AW; Briggs CA; Donnelly-Roberts D; Radek RJ; Marsh KC; Kyncl J
Alzheimer Dis Assoc Disord; 1995; 9 Suppl 2():50-61. PubMed ID: 8534424
[TBL] [Abstract][Full Text] [Related]
15. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.
Abreo MA; Lin NH; Garvey DS; Gunn DE; Hettinger AM; Wasicak JT; Pavlik PA; Martin YC; Donnelly-roberts DL; Anderson DJ; Sullivan JP; Williams M; Arneric SP; Holladay MW
J Med Chem; 1996 Feb; 39(4):817-25. PubMed ID: 8632405
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices.
Sacaan AI; Dunlop JL; Lloyd GK
J Pharmacol Exp Ther; 1995 Jul; 274(1):224-30. PubMed ID: 7542334
[TBL] [Abstract][Full Text] [Related]
17. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.
Wilkins LH; Grinevich VP; Ayers JT; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2003 Jan; 304(1):400-10. PubMed ID: 12490617
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.
Rao TS; Adams PB; Correa LD; Santori EM; Sacaan AI; Reid RT; Cosford ND
Brain Res; 2008 Oct; 1234():16-24. PubMed ID: 18692487
[TBL] [Abstract][Full Text] [Related]
19. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization.
Bencherif M; Lovette ME; Fowler KW; Arrington S; Reeves L; Caldwell WS; Lippiello PM
J Pharmacol Exp Ther; 1996 Dec; 279(3):1413-21. PubMed ID: 8968366
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
